ACTU Actuate Therapeutics Inc.: Earnings per share for the trailing year

This price chart illustrates the EPS dynamics of Actuate Therapeutics, Inc. (ACTU), whose metrics currently reach 35.70. The biopharmaceutical business is based on creating innovative GSK-3 inhibitors for the therapy of complex tumors. The absence of approved analogs in the niche spares the startup from price wars. Success is ensured by a team of leading oncologists who possess full creative freedom and financial guarantees.
Financial and market metric breakdowns for Actuate Therapeutics, Inc (ACTU)

Developing oncology drugs requires colossal clinical trial expenditures, which directly impacts the net income of Actuate Therapeutics, Inc. (ACTU). The algorithm calculates the rolling annual change in earnings per share, neutralizing time gaps between quarterly reports. This metric determines the pace of business scaling, signaling a potential asset revaluation during sharp spikes. By analyzing the trend of the annual percentage change in EPS TTM, an investor assesses the real efficiency of patent capitalization.